real-time news and commentary for investors
Wednesday, Feb 27
Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was...
Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was featured in a pessimistic article in Seeking Alpha. The stock actually began its fall on Monday, but was exacerbated yesterday by the SA piece by contributor Robert Schwartz, who noted that PPHM's lead drug candidate, bavituximab, has had twelve Phase-I/-II studies and treated 613 cancer patients but has yet to observe a statistically significant improvement over a contemporary standard-of-care. Schwartz thinks its time to throw in the towel.